Search research articles
Contact Us
Filters
Showing results (61-70 of 104) with videos related to
Page
of 11
Sort By:
The Journal of Investigative Dermatology
|
June 4, 2015
XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation
Manali Phadke, Geoffrey T Gibney, Carolyn J Rich, et al.
Cancer Immunology, Immunotherapy : CII
|
March 14, 2019
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat, Robert Ferguson, Danny Simpson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 22, 2012
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
Shari Pilon-Thomas, Lisa Kuhn, Sabine Ellwanger, et al.
Cancer Immunology Research
|
February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid Tumors
Ryan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Gastrointestinal Endoscopy
|
May 12, 2018
Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer
Toufic Kachaamy, Ravi Prakash, Madappa Kundranda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
John M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Journal for Immunotherapy of Cancer
|
July 11, 2025
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Georgina V Long, Hao Tang, Keyur Desai, et al.
PDA Journal of Pharmaceutical Science and Technology
|
October 27, 2018
Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing
Jeffrey Weber, James Hauschild, Pieta Ijzerman-Boon, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 104) with videos related to
Sort By:
Page
of 11
The Journal of Investigative Dermatology
|
June 4, 2015
XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation
Manali Phadke, Geoffrey T Gibney, Carolyn J Rich, et al.
Cancer Immunology, Immunotherapy : CII
|
March 14, 2019
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat, Robert Ferguson, Danny Simpson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 22, 2012
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
Shari Pilon-Thomas, Lisa Kuhn, Sabine Ellwanger, et al.
Cancer Immunology Research
|
February 14, 2016
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber, Geoffrey Gibney, Ragini Kudchadkar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
Kim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid Tumors
Ryan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Gastrointestinal Endoscopy
|
May 12, 2018
Liquid nitrogen spray cryotherapy for dysphagia palliation in patients with inoperable esophageal cancer
Toufic Kachaamy, Ravi Prakash, Madappa Kundranda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
John M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Journal for Immunotherapy of Cancer
|
July 11, 2025
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
Georgina V Long, Hao Tang, Keyur Desai, et al.
PDA Journal of Pharmaceutical Science and Technology
|
October 27, 2018
Continuous Microbiological Environmental Monitoring for Process Understanding and Reduced Interventions in Aseptic Manufacturing
Jeffrey Weber, James Hauschild, Pieta Ijzerman-Boon, et al.
Page
of 11